Johnson & Johnson's string of talc wins has come to an end as a judge in Missouri upheld a $110 million verdict against the company.
As biopharma grapples with a widespread gender diversity problem, Alkermes faces three lawsuits alleging discriminatory treatment toward female employees.
Three major regulatory bodies – FDA, EMA and Health Canada – changed their guidelines to drug naming. How could these changes impact drug launch timelines?
The Supreme Court is set to decide whether the controversial inter partes review process is constitutional.
AmerisourceBergen has added $50 million more to resolve a DOJ probe into sales of cancer meds, taking its total in the matter to $885 million.
Allergan's anticompetitive behavior didn't begin with its tribal licensing deal to protect Restasis from rivals, a new lawsuit alleges.
Pfizer faces a legal hurdle to its proposed Herceptin biosimilar now that Roche has sued for patent infringement.
A federal judge rebuffed Aegerion's proposed $36M marketing settlement, saying it highlights a "two-tier criminal justice system."
Facing a rash of lawsuits claiming aggressive opioid marketing led to a nationwide epidemic, Purdue Pharma is reportedly initiating settlement talks.
Endo received good news this week in a lawsuit alleging wrongdoing in how it marketed its testosterone drug Testim.
As the number of pending talc cases continues to tick upward, Johnson & Johnson is maintaining its defensive winning streak.